Abstract

Background

Previous research in a number of countries has suggested considerable variability in prescribing patterns of antimalarial drugs. The aim of this study was to investigate the trends in prescription of antimalarial drugs recommended for chemoprophylaxis in Australia from 1998 to 2002.

Methods

In 2005 data was extracted from the online Australian Statistics on Medicines reports published by the Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-committee, on antimalarials used in Australia from 1998 to 2002.

Results

Doxycycline probably remains the malaria chemoprophylaxis of choice prescribed for Australians visiting multiple drug–resistant malarious areas. Over the past 10 years, there has been marked drop in the prescription of less useful antifolate drugs such as pyrimethamine combination antimalarial drugs, especially pyrimethamine plus dapsone, which was withdrawn by 1999. There has also been a reduction in the number of prescriptions for chloroquine, mefloquine, and proguanil. The number of prescriptions for atovaquone and proguanil remain small, although they have increased steadily since its introduction in 2000, in the absence of a recommendation in the prevailing Australian guidelines.

Conclusions

The prescription of antimalarials such as proguanil, chloroquine, mefloquine, and the pyrimethamine-containing compounds reduced considerably between 1998 and 2002. This was probably largely influenced by the availability of antimalarials, increasing resistance, the issuing of updated guidelines for malaria chemoprophylaxis, and continuing education. Newer drugs such as atovaquone plus proguanil may displace older antimalarials, particularly in the prevention of Plasmodium falciparum infection.

References

1
World Health Organization. Malaria. Fact sheet no. 94. Available at. http://www.who.int/mediacentre/factsheets/fs094/en/print.html. (Accessed 2005 Feb 8).
2
Australian Bureau of Statistics. 9.25 National Notifiable Disease Surveillance System reports—1998 to 2000.
Year Book Australia 2002. Catalogue No. 1301.0
. Canberra.
Australian Government Publishing Service
,
2002
.
3
Australian Bureau of Statistics. 9.27 National Notifiable Disease Surveillance System 2eports.
Year Book Australia. Catalogue No. 1301.0
. Canberra.
Australian Government Publishing Service
,
2005
.
4
Harvey
B
.
Trends in malaria in Australia, 1991–1997
.
Commun Dis Intell
 
1998
;
22
:
247
248
.
5
Charles
DM
Hart
J
Davis
WA
et al.
Notifications of imported malaria in Western Australia, 1990–2001. incidence, associated factors and chemoprophylaxis
.
Med J Aust
 
2005
;
182
:
164
167
.
6
Lewis
SJ
Davidson
RN
Ross
EJ
Hall
AP
.
Severity of imported malaria. effect of taking antimalarial prophylaxis
.
BMJ
 
1992
;
305
:
741
3
.
7
Davis
TM
Breheny
FX
Kendal
PA
et al.
Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate
.
Med J Aust
 
1997
;
166
:
416
418
.
8
Robinson
P
Jenney
AW
Tachado
M
et al.
Imported malaria treated in Melbourne, Australia. epidemiology and clinical features in 246 patients
.
J Travel Med
 
2000
;
8
:
76
81
.
9
Commonwealth Department of Health.
Health information for international travel, 1995
.
4th Ed.
Canberra.
Australian Government Publishing Service
,
1994
.
10
Harvey
K
.
Therapeutic guidelines. antibiotic
.
10th Ed.
North Melbourne :
Therapeutic Guidelines Limited
,
1998
.
11
Spicer
J
.
Therapeutic guidelines. antibiotic. Version 11
. North Melbourne :
Therapeutic Guidelines Limited
,
2000
.
12
McCall
BJ
Pearce
MC
.
Malaria treatment in Queensland, 1992. The use of malaria treatment guidelines
.
Med J Aust
 
1994
;
161
:
259
262
.
13
Leggat
PA
Speare
R
.
Trends in antimalarial drugs prescribed in Australia, 1992–1998
.
J Travel Med
 
2003
;
10
:
189
191
.
14
Australian Bureau of Statistics.
Australian Bureau of Statistics. 21.14 Australians travelling abroad. Year Book Australia. Catalogue No. 1301.0
. Canberra.
Australian Government Publishing Service
,
2004
.
15
Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee. Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee.
Australian statistics on medicines 1998
. Canberra.
Australian Government Publishing Service
,
2000
.
16
Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee. Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee.
Australian Statistics on Medicines 1999–2000
. Canberra.
Australian Government Publishing Service
,
2003
.
17
Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee. Pharmaceutical Benefits Advisory Committee, Drug Utilization Sub-Committee.
Australian Statistics on Medicines 2001–2002
. Canberra.
Australian Government Publishing Service
,
2004
.
18
Williams
A
Lewis
DJM
.
Malaria prophylaxis. a postal questionnaire survey of general practitioners in South Wales
.
BMJ
 
1987
;
295
:
1449
1452
.
19
Leggat
PA
Heydon
JL
.
Trends in antimalarial drugs prescribed in New Zealand 1993–1998
.
J Travel Med
 
2002
;
9
:
156
159
.
20
Leggat
PA
Dürrheim
DN
Blumberg
L
.
Trends in malaria chemoprophylaxis prescription in South Africa 1994–2000
.
J Travel Med
 
2002
;
9
:
318
321
.
21
Coole
L
Wiselka
MJ
Nicholson
KG
.
Malaria prophylaxis in travellers from Britain
.
J Infect
 
1989
;
18
:
209
212
.
22
Phillips-Howard
PA
West
LJ
.
Severe adverse reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and amodiaquine in Britain
.
J R Soc Med
 
1990
;
83
:
82
85
.
23
Athan
E
Durrheim
DN
Barnes
K
et al.
Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa
.
S Afr Med J
 
2001
;
91
:
592
594
.
24
Kain
KC
.
Prophylactic drugs for malaria. why do we need another one
.
J Travel Med
 
1999
;
6
(
Suppl 1
):
S2
S7
.
25
Edstein
MD
Nasveld
PE
Rieckmann
KH
.
The challenge of effective chemoprophylaxis against malaria
.
Aust Def Force Health
 
2001
;
2
:
12
16
.
26
Dürrheim
DN
Leggat
PA
Shanks
GD
. Malaria prevention. In.
Leggat
PA
,
Goldsmid
JM
, eds.
Primer of travel medicine
.
3rd Ed
. Brisbane :
ACTM Publications
,
2002
:
38
54
.
27
Spicer
J
.
Therapeutic guidelines. antibiotic. Version 12
. North Melbourne :
Therapeutic Guidelines Limited
,
2003
.